Temporomandibular Disorder
Conditions
Keywords
TMD, collagen, intramuscular injection, trigger point
Brief summary
An intramusclular injection of three solutions were performed( collagen, lidocaine, saline) in musculoskeletal trigger points, in patients suffering from temporomandibular disorders(TMD). Best results were observed in collagen group: reduction of 59,2% sEMG activity of masseter muscles and 53,75% reduction of pain intensity in VAS scale.
Detailed description
Collagen is an important component, building myocytes and extracellular matrix of skeletal muscles. The novel treatment option for trigger point therapy and muscle regeneration in TMD patients are intramuscular collagen injections. The aim of the study was to evaluate the efficacy of intramuscular injections of Collagen MD Muscle(Guna) 2 ml, 2 ml of Lidocainum 2% without vasoconstrictor and 2 ml of Saline (0,9 % NaCl). 43 patients were enrolled to the study (17 male and 26 female, 40 +/- 3,8 years old). The masseter muscle activity was measured with sEMG Neurobit Optima 4 (Neurobit System). Visual Analogue Scale was used to determine pain intensity changes between follow-up visits in each group. Trigger points were localized with palpation of masseter muscle. Electromyographic activity of masseter muscle was measured before injections on each visit: 0, 7,14 days. In our analysis sEMG masseter muscle activity was significantly decreased: in collagen group 59,2%, in lidocainum group 39,3% and in saline group14%. Pain intensity reduction in VAS scale was 53,75% in collagen group, in lidocainum group 25% and in saline group 20,1%.
Interventions
intramuscular Saline injection
intramusclular injections of MD Muscle collagen
intramuscular Lidocaine 2% injection
Sponsors
Study design
Masking description
Participants and care providers had no knowledge about the substance prepared for the injection. The information for the main investigator was the number of patient and the number of injection
Intervention model description
patients were divided into the three groups and examination and therapy was performed after 7 and 14 days
Eligibility
Inclusion criteria
\- sleep bruxism, DC/TMD myofascial pain, myofascial pain with referral
Exclusion criteria
* younger than 18years old, active orthodonctic treatment,neurological treatment, post radiotherapy, after head trauma within 2 years, patients with unsupported occlusal contacts, addicted to analgesic drugs, with the fear of needle
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| sEMG reduction of masseter muscle in TMD patients | 14 days | reduction of electromyograpic activity of masseter muscle |
Countries
Poland